TFBS Bioscience Inc. (6939) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for TFBS Bioscience Inc. (6939:TWSE), powered by AI.

Current Price
$20.20
Sector
Healthcare
What is the TFBS Bioscience Inc. stock price forecast?

TFBS Bioscience Inc. is currently trading at $20.20. View real-time AI analysis on Alpha Lenz.

What is TFBS Bioscience Inc. insider trading activity?

View the latest insider trading data for TFBS Bioscience Inc. on Alpha Lenz.

What is TFBS Bioscience Inc.'s P/E ratio?

View TFBS Bioscience Inc.'s valuation metrics on Alpha Lenz.

TFBS Bioscience Inc.

TWSE · 6939
NT$20.20+0.10(+0.50%)
Ask about TFBS Bioscience Inc.'s future dividend policy...
Alpha Chat Insight

TFBS Bioscience Inc.'s ROE is -6.2%. Explore profitability and growth together.

Ask for details

Company Overview

TFBS Bioscience Inc. is a contract research organization specializing in advanced biological testing and viral vector manufacturing services. Established in 2016 and headquartered in New Taipei City, Taiwan, the company serves the biotechnology and pharmaceutical sectors by supporting the development and production needs of cell and gene therapy products, vaccines, and other biologics. TFBS Bioscience offers a comprehensive suite of services, including biosafety analysis, product release testing, core laboratory support, animal studies, and both good manufacturing practice (GMP) and research-grade manufacturing of viral vectors such as AAV, lentivirus, retrovirus, and adenovirus. The company is recognized for being the first in Taiwan to establish a dedicated facility for viral vector contract development and manufacturing, providing fully integrated, end-to-end development solutions that meet both clinical trial and commercial production requirements. With a strong foundation in regulatory compliance and technical expertise rooted in Taiwan’s leading research institutions, TFBS Bioscience plays a vital role in accelerating the development, safety validation, and market entry of innovative biopharmaceutical therapies across the Asia-Pacific region.

CEODr. Tatung Yuan Ph.D.
SectorHealthcare
IndustryDiagnostics & Research
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$193.14MRevenue
0.00Shares Out
0Employees

Margins

19.06%Gross
-9.97%EBITDA
-40.39%Operating
-38.28%Pre-Tax
-38.58%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-8.57%Rev 3Yr
10.25%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-5.04%ROA
-6.22%ROE
-4.81%ROIC

Financial Health

NT$307.32MCash & Cash Equivalents
NT$-12.60MNet Debt
25.32%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

TFBS Bioscience Inc. (ticker: 6939) is a company listed on TWSE in the Healthcare sector (Diagnostics & Research).

The current price is 20.2 with a P/E ratio of -x and P/B of -x.

ROE is -6.22% and operating margin is -40.39%. Annual revenue is $193M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
TFBS Bioscience Inc. (6939) Stock Forecast 2026 $20.20 — Price, Financials & Analyst Targets | Alpha Lenz